Diabetes Monitoring Devices Market

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the diabetes monitoring devices market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to diabetes and a discussion on the various existing challenges in diabetes monitoring. Additionally, it features brief descriptions of various diabetes monitoring devices and concludes with a discussion on the future trends that are likely to impact this emerging market segment. 

Chapter 4 includes an assessment of current market landscape of the diabetes monitoring devices, based on various parameters, such as type of device (self-monitoring blood glucose device and continuous blood glucose monitoring devices), current status of development (preclinical, clinical and marketed), target patient segment (children, adults and elderly patients), analyte procurement (invasive, non-invasive and minimally invasive), volume of analyte used (less than 0.8 µL, 0.8 to 2 µL and more than 2 µL), processing speed (fast and slow), wearability (wearable and non-wearable), wireless connectivity, water resistance potential, provision for alerts / alarms, device memory attributes and glucose measurement range. In addition, the report presents the details of the companies developing these devices, including information on type of developer (industry and non-industry), year of establishment, company size, location of headquarters and leading developers. 

Chapter 5 presents a detailed competitiveness analysis of diabetes monitoring devices based on various relevant parameters, such as supplier power (based on the experience / expertise of the developer) and product specifications (type of device, current status of development, target patient segment, analyte procurement, volume of analyte used, processing speed, wireless connectivity, water resistance potential, provision for alerts / alarms and device memory attributes). 

Chapter 6 features an analysis of the various partnerships and collaborations that have been inked amongst players in this domain, in the time period 2015-2020 (till August). It provides a brief description on the various types of partnership models (product / technology integration agreements, commercialization agreements, distribution agreements, product development agreements, acquisitions, product development and commercialization agreements and other relevant types of deals) that have been adopted by stakeholders in this domain. Further, it includes analyses based on year of partnership, type of partnership, type of device mentioned in the agreement and most active players. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents. 

Chapter 7 provides detailed profiles of the prominent companies that develop diabetes monitoring devices. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook. 

Chapter 8 provides a review of recent initiatives undertaken by big pharma players in this domain. It also features a benchmark analysis of top 10 big pharma players (in terms of annual revenues of 2019), comparing them across various relevant parameters, such as diversity of device portfolio number of marketed diabetes and clinical-stage diabetes drugs, diabetes type, type of diabetes drug evaluated and partnerships.

Chapter 9 presents an insightful market forecast analysis, highlighting the future potential of diabetes monitoring devices till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of device (self-monitoring blood glucose device and continuous glucose monitoring device), [B] diabetes type (type 1 diabetes and type 2 diabetes), [C] device component (self-monitoring blood glucose devices: glucose meters, test strips and lancets; continuous glucose monitoring devices: sensors, transmitters and receivers) and [D] key geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa and rest of the world).

Chapter 10 is a summary of the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the diabetes monitoring devices market.

Chapter 11 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Ambuj Jain (General Manager-Business Development, Cambridge Consultants), Ron Erickson (Founder and Chairman, Know Labs)

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Diabetes
3.2.1. Classification of Diabetes
3.2.1.1. Type 1 Diabetes
3.2.1.2. Type 2 Diabetes
3.2.1.3. Gestational Diabetes 

3.3. Key Challenges Associated with Diabetes Monitoring
3.4. Diabetes Monitoring Devices
3.4.1. Devices for Self-Monitoring of Blood Glucose Levels
3.4.1.1. Blood Glucose Meter
3.4.1.2. Testing Strips
3.4.1.3. Lancets

3.4.2. Continuous Blood Glucose Monitoring Devices
3.4.2.1. Sensors
3.4.2.2. Transmitters
3.4.2.3. Receivers
3.4.2.4. Patches

3.5. Future Perspectives

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Diabetes Monitoring Devices: Overall Market Landscape
4.2.1. Analysis by Type of Device
4.2.2. Analysis by Current Status of Development
4.2.3. Analysis by Target Patient Segment
4.2.4. Analysis by Analyte Procurement
4.2.5. Analysis by Volume of Analyte Used
4.2.6. Analysis by Processing Speed
4.2.7. Analysis by Wearability
4.2.8. Analysis by Wireless Connectivity
4.2.9. Analysis by Water Resistance Potential
4.2.10. Analysis by Provisions for Alerts / Alarms 
4.2.11. Analysis by Device Memory Attributes 
4.2.12. Analysis by Glucose Measurement Range 

4.3. Diabetes Monitoring Devices: List of Developers
4.3.1. Analysis by Type of Developer
4.3.2. Analysis by Year of Establishment
4.3.3. Analysis by Company Size
4.3.4. Analysis by Geographical Location
4.3.5. Leading Developers: Analysis by Number of Products

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Methodology
5.2.1. Product Competitiveness Analysis: Diabetes Monitoring Devices
5.2.1.1. Product Competitiveness Analysis: Continuous Blood Glucose Monitoring Devices 
5.2.1.2. Product Competitiveness Analysis: Self-Monitoring Blood Glucose Devices 

6. PARTNERSHIPS AND COLLABORATIONS
6.1. Chapter Overview
6.2. Partnership Models
6.3. Diabetes Monitoring Devices: List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.3. Analysis by Year and Type of Partnership
6.3.4. Analysis by Type of Device
6.3.5. Most Active Players: Analysis by Number of Partnerships
6.3.6. Geographical Analysis
6.3.6.1. Region-wise Distribution
6.3.6.2. Country-wise Distribution

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. ApexBio
7.2.1. Company Overview
7.2.2. Diabetes Monitoring Devices Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. Ascensia Diabetes Care
7.3.1. Company Overview
7.3.2. Diabetes Monitoring Devices Portfolio
7.3.3. Recent Developments and Future Outlook

7.4. i-SENS
7.4.1. Company Overview
7.4.2. Diabetes Monitoring Devices Portfolio
7.4.3. Recent Developments and Future Outlook

7.5. Oak Tree Health
7.5.1. Company Overview
7.5.2. Diabetes Monitoring Devices Portfolio
7.5.3. Recent Developments and Future Outlook

7.6. SD Biosensor
7.6.1. Company Overview
7.6.2. Diabetes Monitoring Devices Portfolio
7.6.3. Recent Developments and Future Outlook

7.7. TaiDoc Technology
7.7.1. Company Overview
7.7.2. Diabetes Monitoring Devices Portfolio
7.7.3. Recent Developments and Future Outlook

7.8. VivaCheck Laboratories 
7.8.1. Company Overview
7.8.2. Diabetes Monitoring Devices Portfolio
7.8.3. Recent Developments and Future Outlook

8. DIABETES MONITORING DEVICES RELATED INITIATIVES OF BIG PHARMA PLAYERS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Initiatives of Big Pharma Players
8.3.1. Analysis by Type of Disease Management Solution
8.3.2. Analysis by Number of Marketed and Clinical-Stage Diabetes Drugs
8.3.3. Analysis by Diabetes Type
8.3.4. Analysis by Type of Drug
8.3.5. Analysis by Number of Partnerships

8.4. Competitive Benchmarking of Big Pharma Players
8.4.1. Spider Web Analysis: Company A
8.4.2. Spider Web Analysis: Company B
8.4.3. Spider Web Analysis: Company C
8.4.4. Spider Web Analysis: Company D
8.4.5. Spider Web Analysis: Company E

9. MARKET SIZING AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Assumptions
9.3. Overall Diabetes Monitoring Devices Market, 2020-2030
9.4. Diabetes Monitoring Devices Market, 2020-2030: Distribution by Type of Device
9.5. Overall Self-Monitoring Blood Glucose Devices Market, 2020-2030
9.5.1. Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Diabetes Type
9.5.2. Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Device Component 
9.5.3. Self-Monitoring Blood Glucose Devices Market, 2020-2030: Geographical Distribution
9.5.3.1. Self-Monitoring Blood Glucose Devices Market in North America, 2020-2030
9.5.3.2. Self-Monitoring Blood Glucose Devices Market in Europe, 2020-2030
9.5.3.3. Self-Monitoring Blood Glucose Devices Market in Asia Pacific, 2020-2030
9.5.3.4. Self-Monitoring Blood Glucose Devices Market in Latin America, 2020-2030
9.5.3.5. Self-Monitoring Blood Glucose Devices Market in Middle East and North Africa, 2020-2030
9.5.3.6. Self-Monitoring Blood Glucose Devices Market in Rest of the World, 2020-2030

9.6. Overall Continuous Blood Glucose Monitoring Devices Market, 2020-2030
9.6.1. Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Diabetes Type
9.6.2. Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Device Component
9.6.3. Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Geographical Distribution
9.6.3.1. Continuous Blood Glucose Monitoring Devices Market in North America, 2020-2030
9.6.3.2. Continuous Blood Glucose Monitoring Devices Market in Europe, 2020-2030
9.6.3.3. Continuous Blood Glucose Monitoring Devices Market in Asia Pacific, 2020-2030
9.6.3.4. Continuous Blood Glucose Monitoring Devices Market in Latin America, 2020-2030
9.6.3.4. Continuous Blood Glucose Monitoring Devices Market in Middle East and North Africa, 2020-2030
9.6.3.6. Continuous Blood Glucose Monitoring Devices Market in Rest of the World, 2020-2030

10. CONCLUDING REMARKS
10.1. Chapter Overview
10.2. Key Takeaways

11. EXECUTIVE INSIGHTS
11.1. Chapter Overview
11.2. Cambridge Consultants
11.2.1. Company Snapshot
11.2.2. Interview Transcript: Ambuj Jain, General Manager- Business Development

11.3. Know Labs
11.3.1. Company Snapshot
11.3.2. Interview Transcript: Ron Erickson, Founder and Chairman

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 4.1 Diabetes Monitoring Devices: Distribution by Type of Device
Figure 4.2 Diabetes Monitoring Devices: Distribution by Current Status of Development
Figure 4.3 Diabetes Monitoring Devices: Distribution by Type of Device and Current Status of Development
Figure 4.4 Diabetes Monitoring Devices: Distribution by Target Patient Segment
Figure 4.5 Diabetes Monitoring Devices: Distribution by Type of Device and Target Patient Segment
Figure 4.6 Diabetes Monitoring Devices: Distribution by Analyte Procurement
Figure 4.7 Diabetes Monitoring Devices: Distribution by Type of Device and Analyte Procurement
Figure 4.8 Diabetes Monitoring Devices: Distribution by Volume of Analyte Used
Figure 4.9 Diabetes Monitoring Devices: Distribution by Processing Speed
Figure 4.10 Diabetes Monitoring Devices: Distribution by Type of Device and Processing Speed
Figure 4.11 Diabetes Monitoring Devices: Distribution by Wearability
Figure 4.12 Diabetes Monitoring Devices: Distribution by Wireless Connectivity
Figure 4.13 Diabetes Monitoring Devices: Distribution by Type of Device and Wireless Connectivity
Figure 4.14 Diabetes Monitoring Devices: Distribution by Water Resistance Potential
Figure 4.15 Diabetes Monitoring Devices: Distribution by Type of Device and Water Resistance Potential
Figure 4.16 Diabetes Monitoring Devices: Distribution by Provisions for Alerts / Alarms
Figure 4.17 Diabetes Monitoring Devices: Distribution by Type of Device and Provisions for Alerts / Alarms
Figure 4.18 Diabetes Monitoring Devices: Distribution by Device Memory Attributes
Figure 4.19 Diabetes Monitoring Devices: Distribution by Glucose Measurement Range
Figure 4.20 Diabetes Monitoring Device Developers: Distribution by Type of Stakeholder
Figure 4.21 Diabetes Monitoring Device Developers: Distribution by Year of Establishment
Figure 4.22 Diabetes Monitoring Device Developers: Distribution by Company Size
Figure 4.23 Diabetes Monitoring Device Developers: Geographical Distribution by Location of Headquarters
Figure 4.24 Leading Developers: Analysis by Number of Products
Figure 5.1 Continuous Blood Glucose Monitoring Devices: Dot Plot Analysis
Figure 5.2 Product Competitiveness Analysis: Continuous Blood Glucose Monitoring Devices
Figure 5.3 Self-Monitoring Blood Glucose Devices: Dot Plot Analysis
Figure 5.4 Product Competitiveness Analysis: Self-Monitoring Blood Glucose Devices
Figure 6.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 6.4 Partnerships and Collaborations: Distribution by Type of Device
Figure 6.5 Most Active Players: Analysis by Number of Partnerships
Figure 6.6 Partnerships and Collaborations: Region-wise Distribution
Figure 6.7 Partnerships and Collaborations: Country-wise Distribution
Figure 8.1 Big Pharma Initiatives: Heat Map Analysis of Top Pharmaceutical Companies
Figure 8.2 Big Pharma Initiatives: Distribution by Type of Disease Management Solution
Figure 8.3 Big Pharma Initiatives: Distribution by Number of Marketed and Clinical-Stage Diabetes Drugs
Figure 8.4 Big Pharma Initiatives: Distribution by Diabetes Type
Figure 8.5 Big Pharma Initiatives: Distribution by Type of Drug
Figure 8.6 Big Pharma Initiatives: Distribution by Number of Partnerships
Figure 8.7 Spider Web Analysis: Company A
Figure 8.8 Spider Web Analysis: Company B
Figure 8.9 Spider Web Analysis: Company C
Figure 8.10 Spider Web Analysis: Company D
Figure 8.11 Spider Web Analysis: Company E
Figure 9.1 Overall Diabetes Monitoring Devices Market, 2020-2030 (USD Billion)
Figure 9.2 Diabetes Monitoring Devices Market, 2020-2030: Distribution by Type of Device (USD Billion)
Figure 9.3 Overall Self-Monitoring Blood Glucose Devices Market, 2020-2030 (USD Billion)
Figure 9.4 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Diabetes Type (USD Billion)
Figure 9.5 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Device Component (USD Billion)
Figure 9.6 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Geographical Distribution (USD Billion)
Figure 9.7 Self-Monitoring Blood Glucose Devices Market in North America, 2020-2030 (USD Billion)
Figure 9.8 Self-Monitoring Blood Glucose Devices Market in Europe, 2020-2030 (USD Billion)
Figure 9.9 Self-Monitoring Blood Glucose Devices Market in Asia Pacific, 2020-2030 (USD Billion)
Figure 9.10 Self-Monitoring Blood Glucose Devices Market in Latin America, 2020-2030 (USD Billion)
Figure 9.11 Self-Monitoring Blood Glucose Devices Market in Middle East and North Africa, 2020-2030 (USD Billion)
Figure 9.12 Self-Monitoring Blood Glucose Devices Market in Rest of the World, 2020-2030 (USD Billion)
Figure 9.13 Overall Continuous Blood Glucose Monitoring Devices Market, 2020-2030 (USD Billion)
Figure 9.14 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Diabetes Type (USD Billion)
Figure 9.15 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Device Component (USD Billion)
Figure 9.16 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Geographical Distribution (USD Billion)
Figure 9.17 Continuous Blood Glucose Monitoring Devices Market in North America, 2020-2030 (USD Billion)
Figure 9.18 Continuous Blood Glucose Monitoring Devices Market in Europe, 2020-2030 (USD Billion)
Figure 9.19 Continuous Blood Glucose Monitoring Devices Market in Asia Pacific, 2020-2030 (USD Billion)
Figure 9.20 Continuous Blood Glucose Monitoring Devices Market in Latin America, 2020-2030 (USD Billion)
Figure 9.21 Continuous Blood Glucose Monitoring Devices Market in Middle East and North Africa, 2020-2030 (USD Billion)
Figure 9.22 Continuous Blood Glucose Monitoring Devices Market in Rest of the World, 2020-2030 (USD Billion)
Figure 10.1 Diabetes Monitoring Device Market: Concluding Remarks

List Of Tables

Table 3.1 Blood Sugar Levels in Diabetic Patients
Table 3.2 Difference between Self-Monitoring and Continuous Monitoring Devices
Table 3.3 Glucose Monitoring Times and Frequency
Table 4.1 List of Diabetes Monitoring Devices
Table 4.2 Diabetes Monitoring Devices: List of Developers
Table 6.1 Diabetes Monitoring Devices: List of Partnerships, 2015-2020 (Till August)
Table 7.1 Leading Diabetes Monitoring Device Developers
Table 7.2 ApexBio: Company Overview
Table 7.3 ApexBio: Diabetes Monitoring Devices
Table 7.4 Ascensia Diabetes Care: Company Overview
Table 7.5 Ascensia Diabetes Care: Diabetes Monitoring Devices
Table 7.6 Ascensia Diabetes Care: Recent Developments and Future Outlook
Table 7.7 i-SENS: Company Overview
Table 7.8 i-SENS: Diabetes Monitoring Devices
Table 7.9 i-SENS: Recent Developments and Future Outlook
Table 7.10 Oak Tree Health: Company Overview
Table 7.11 Oak Tree Health: Diabetes Monitoring Devices
Table 7.12 SD Biosensor: Company Overview
Table 7.13 SD Biosensor: Diabetes Monitoring Devices
Table 7.14 SD Biosensor: Recent Developments and Future Outlook
Table 7.15 TaiDoc Technology: Company Overview
Table 7.16 TaiDoc Technology: Diabetes Monitoring Devices
Table 7.17 VivaChek Laboratories: Company Overview
Table 7.18 VivaChek Laboratories: Diabetes Monitoring Devices
Table 7.19 VivaChek Laboratories: Recent Developments and Future Outlook
Table 8.1 Top Big Pharma Players in Diabetes Domain
Table 8.2 Big Pharma Players: Spider-Web Analysis (Input Data)
Table 11.1 Cambridge Consultants: Company Snapshot
Table 11.2 Know Labs: Company Snapshot
Table 12.1 Diabetes Monitoring Devices: Distribution by Type of Device
Table 12.2 Diabetes Monitoring Devices: Distribution by Current Status of Development
Table 12.3 Diabetes Monitoring Devices: Distribution by Type of Device and Current Status of Development
Table 12.4 Diabetes Monitoring Devices: Distribution by Target Patient Segment
Table 12.5 Diabetes Monitoring Devices: Distribution by Type of Device and Target Patient Segment
Table 12.6 Diabetes Monitoring Devices: Distribution by Analyte Procurement
Table 12.7 Diabetes Monitoring Devices: Distribution by Type of Device and Analyte Procurement
Table 12.8 Diabetes Monitoring Devices: Distribution by Volume of Analyte Used
Table 12.9 Diabetes Monitoring Devices: Distribution by Processing Speed
Table 12.10 Diabetes Monitoring Devices: Distribution by Type of Device and Processing Speed
Table 12.11 Diabetes Monitoring Devices: Distribution by Wearability
Table 12.12 Diabetes Monitoring Devices: Distribution by Wireless Connectivity
Table 12.13 Diabetes Monitoring Devices: Distribution by Type of Device and Wireless Connectivity
Table 12.14 Diabetes Monitoring Devices: Distribution by Water Resistance Potential
Table 12.15 Diabetes Monitoring Devices: Distribution by Type of Device and Water Resistance Potential
Table 12.16 Diabetes Monitoring Devices: Distribution by Provisions for Alerts / Alarms
Table 12.17 Diabetes Monitoring Devices: Distribution by Type of Device and Provisions for Alerts / Alarms
Table 12.18 Diabetes Monitoring Devices: Distribution by Distribution by Device Memory Attributes
Table 12.19 Diabetes Monitoring Devices: Distribution by Glucose Measurement Range
Table 12.20 Diabetes Monitoring Device Developers: Distribution by Type of Stakeholder
Table 12.21 Diabetes Monitoring Device Developers: Distribution by Year of Establishment
Table 12.22 Diabetes Monitoring Device Developers: Distribution by Company Size
Table 12.23 Diabetes Monitoring Device Developers: Geographical Distribution by Location of Headquarters
Table 12.24 Leading Developers: Analysis by Number of Products
Table 12.25 Partnerships and Collaborations: Distribution by Year of Partnership
Table 12.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.27 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 12.28 Partnerships and Collaborations: Distribution by Type of Device
Table 12.29 Most Active Players: Analysis by Number of Partnerships
Table 12.30 Partnerships and Collaborations: Region-wise Distribution
Table 12.31 Partnerships and Collaborations: Country-wise Distribution
Table 12.32 Overall Diabetes Monitoring Devices Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.33 Diabetes Monitoring Devices Market, 2020-2030: Distribution by Type of Device (USD Billion)
Table 12.34 Overall Self-Monitoring Blood Glucose Devices Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.35 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Diabetes Type (USD Billion)
Table 12.36 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Device Component (USD Billion)
Table 12.37 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Geographical Distribution (USD Billion)
Table 12.38 Self-Monitoring Blood Glucose Devices Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.39 Self-Monitoring Blood Glucose Devices Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.40 Self-Monitoring Blood Glucose Devices Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.41 Self-Monitoring Blood Glucose Devices Market in Latin America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.42 Self-Monitoring Blood Glucose Devices Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.43 Self-Monitoring Blood Glucose Devices Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.44 Overall Continuous Blood Glucose Monitoring Devices Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.45 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Diabetes Type (USD Billion)
Table 12.46 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Device Component (USD Billion)
Table 12.47 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Geographical Distribution (USD Billion)
Table 12.48 Continuous Blood Glucose Monitoring Devices Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.49 Continuous Blood Glucose Monitoring Devices Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.50 Continuous Blood Glucose Monitoring Devices Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.51 Continuous Blood Glucose Monitoring Devices Market in Latin America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 12.52 Continuous Blood Glucose Monitoring Devices Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion
Table 12.53 Continuous Blood Glucose Monitoring Devices Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report. 

1. Abbott
2. ABOX
3. ACON Laboratories
4. AgaMatrix
5. AlDanah Medical
6. Alertgy
7. APExBIO
8. Apple
9. Arcadia Group
10. ArKl Medical
11. ARKRAY
12. Ascensia Diabetes Care
13. BeatO
14. Beurer
15. Bigfoot Biomedical
16. Biolinq
17. Blue Cross and Blue Shield of Minnesota
18. Bruno Farmaceutici 
19. BTNX
20. CEI Technology
21. Cellnovo Group
22. Chemglass Life Sciences
23. CnogaCare
24. Companion Medical
25. Control D
26. CuraTec Nordic
27. Current Health
28. Dallas Burston Ethitronix 
29. DarioHealth
30. Debiotech 
31. Dexcom
32. Diabeto
33. DiaMonTech 
34. Diasend
35. Diathrive
36. DKSH
37. Dnurse Technology
38. Echo Therapeutics
39. Eli Lilly
40. EPS Biotechnology 
41. Essenlife Bioscience
42. Fitbit
43. Fleming Medical
44. ForaCare
45. Fudakang Industrial
46. GE Healthcare
47. Glooko
48. GlucoRx
49. Glucosense Diagnostics
50. Glucovation
51. Gluco-Z
52. GluSense
53. GlySens
54. GlySure
55. Glytec
56. GraphWear Technologies
57. Guangzhou Guang Yuan Biological Pharmaceutical
58. Hangzhou Sejoy Electronics & Instruments
59. Health Alliance Plan
60. Health2Sync
61. Hello Heart
62. Henry Schein Medical
63. HoyHealth
64. IBM
65. Indigo 
66. Infinovo Medical
67. Inside Biometrics
68. Insulet
69. Integrated Medical Sensors
70. Integrity Applications
71. i-SENS
72. JDRF
73. Keto-Mojo
74. Klue
75. Know Labs
76. KTH Royal Institute of Technology
77. LG Life Sciences
78. LifeCaring Technologies 
79. LifePlus
80. LifeScan
81. Livongo Health
82. MediReva
83. MediVena
84. Medtronic
85. Medtrum Technologies
86. META
87. Metronom Health
88. Millennium Medical Supplies
89. Morepen Laboratories
90. National Diagnostic Products
91. Nemaura Medical
92. NovioSense
93. Novo Nordisk
94. Nutrino Health (acquired by Medtronic)
95. Oak Tree Health
96. OK Biotech
97. Omada Health
98. One Drop
99. Pacific Diabetes Technologies
100. Palmdoc
101. PercuSense
102. Pinnacle Technology
103. PKvitality
104. POCTech 
105. Prediktor Medical
106. Prodigy Diabetes Care
107. Qualcomm Life 
108. Quattro Folia
109. Roche
110. Rubin Medical
111. SanaVita Medical
112. Sano Intelligence
113. Sanofi
114. Sanvita Medical
115. SD BIOSENSOR
116. Senseonics
117. SFC Fluidics
118. Shezhen Jiacom Technology
119. Smart Meter
120. Spirit Health
121. TaiDoc Technology
122. Tandem Diabetes Care 
123. Terumo Medical
124. Tianjin HUAC Healthcare Technology 
125. Tidepool
126. TPMENA
127. Trividia Health
128. University of Bath
129. University of California
130. Validic
131. Verily Life Sciences
132. VivaChek Laboratories
133. Voluntis
134. Welldoc
135. Xuzhou Yongkang Electronic Science Technology
136. Ypsomed